P
ProQR Therapeutics
Biotech & Life Sciences · Leiden, Netherlands · Founded 2012 · IPO 2014
Develops RNA therapies to potentially transform the lives of patients suffering from genetic rare diseases MoreLess
ProQR Therapeutics is a clinical-stage biotechnology company focused on discovering and developing RNA therapies for severe genetic disorders, particularly those affecting the retina. The company operates in the biopharmaceutical sector, targeting rare genetic eye diseases such as Leber congenital amaurosis (LCA) and Usher syndrome. ProQR's business model revolves around advancing its proprietary RNA editing technologies, like Axiomer, through clinical trials and securing regulatory approvals. The company generates revenue through licensing agreements, collaborations, and potential future sales of approved therapies. ProQR primarily serves patients with inherited retinal diseases, healthcare providers, and research institutions. The market it operates in is highly specialized, focusing on genetic ophthalmology. The company's financial health is supported by investments, grants, and strategic partnerships.
Keywords: RNA therapies, genetic disorders, retinal diseases, clinical-stage biotech, Leber congenital amaurosis, Usher syndrome, Axiomer technology, ophthalmology, biopharmaceutical, rare diseases.
Company overview
ProQR Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- Leiden, Netherlands
- Employees
- 203
- Open positions
- 5
- Dealroom signal
- 77.1
Valuation & funding
ProQR Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $50M | — | Eli Lilly | ↗ |
| POST IPO EQUITYOther financing | Dec 2024 | $8.1M | — | Rett Syndrome Research Trust | ↗ |
| PRIVATE PLACEMENT VCOther financing | Oct 2024 | $12M | — | Eli Lilly | ↗ |
| POST IPO EQUITYOther financing | Oct 2024 | $63M | — | Undisclosed | ↗ |
| GRANTOther financing | Jan 2024 | $1M | — | Rett Syndrome Research Trust | ↗ |
| POST IPO EQUITYOther financing | Dec 2022 | Eli Lilly | ↗ | ||
| POST IPO DEBTDebt | Dec 2021 | Kreos Capital · Pontifax Funds | ↗ | ||
| POST IPO EQUITYOther financing | Mar 2021 | Undisclosed | ↗ | ||
| POST IPO DEBTDebt | Jul 2020 | Pontifax Funds | — | ||
| POST IPO EQUITYOther financing | Oct 2019 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $15M | -12.5% | −$42M | -274.3% |
| 2025 | $17M | -15.9% | −$42M | -240% |
| 2024 | $21M | +98.5% | −$27M | -127.6% |
| 2023 | $10M | +98.4% | −$32M | -301.6% |
| 2022 | $5.3M | +100.3% | −$65M | -1236.7% |
| 2021 | $2.6M | -74.6% | −$61M | -2310.2% |
| 2020 | $10M | — | −$54M | -523.3% |
Growth signals
ProQR Therapeutics website traffic
Latest recorded traffic for ProQR Therapeutics is 9.9K monthly website visits, down 10% over the last three months. ProQR Therapeutics's team grew 1% over the past year.
Hiring
Open positions at ProQR Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
ProQR Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
ProQR Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where ProQR Therapeutics has talent and traffic
team presence
In the news
Latest news about ProQR Therapeutics
Recent press, funding announcements, and product moves mentioning ProQR Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about ProQR Therapeutics
An AI-synthesized read of the highest-engagement posts about ProQR Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ProQR Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.